AstraZeneca expands Karolinska partnership – adds obesity research
AstraZeneca is expanding its research collaboration with Karolinska Institutet and Karolinska University Hospital. The pharmaceutical company is now investing just over SEK 30 million in four projects, with obesity added as a new research area.
The strategic partnership between AstraZeneca, Karolinska Institutet and Karolinska University Hospital began in 2024 to strengthen the development of precision medicine in Sweden.
The collaboration covers several therapeutic areas, including cancer, immunology, and cardiovascular, kidney and liver diseases. The partners have worked, among other things, to develop clinical studies and strengthen collaboration in advanced therapies.